Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. the Same Therapy Without Methotrexate

NCT00336024 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00336024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. the Same Therapy Without Methotrexate
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
October 22, 2007
Completion date
September 30, 2025
Enrollment
91 (actual)
Sites
145

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic medulloblastoma, medulloblastoma, supratentorial embryonal tumor, not otherwise specified, untreated childhood supratentorial primitive neuroectodermal tumor